Skip to main content
. 2022 May 18;14(10):2486. doi: 10.3390/cancers14102486

Figure 17.

Figure 17

A possible scheme for multi-targeting PDAC to prevent/reverse chemoresistance. A rational association of drugs will probably enhance gemcitabine anti-cancer effects and reduce resistance. The drugs proposed to be associated with gemcitabine have low or no toxicity at all and would not represent an extra burden for the patient. Furthermore, amiloride and tocilizumab may prevent cancer cachexia [603,604], a frequent occurrence in PDAC.